Spineology included 102 patients in the study who suffered from lumbar DDD for at least six months. Of the study participants, 80 completed 12-month postoperative follow-ups and 27 completed 24-month follow-ups.

Here are three findings:

1. At the primary fusion endpoint, 93 percent with available films were fused.

3. At the 24-month follow-up, 24 of the 27 patients reported "excellent" or "good" patient satisfaction.

With no unanticipated adverse events and no interbody device-related serious adverse events, Dr. Chi concluded, "We have found this innovative minimally invasive graft contaminant device to be a safe and effective option for lumbar interbody fusion procedures."